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Food allergy (FA) is relatively a common disease in infants, but eﬀective drug therapies are not yet available. Notably, mucosal
mast cells, but not connective-tissue mast cells, play important roles in food allergic reactions via the release of inﬂammatory
mediators. Therefore, we screened medicinal herb extracts for in vitro and in vivo antiallergic activity through inhibiting mucosal
mast cell activation. As a result, both antigen-induced and calcium ionophore-induced degranulation was signiﬁcantly inhibited
by Zanthoxyli Fructus water extract (ZF) in mucosal-type murine bone marrow-derived mast cells (mBMMCs). ZF suppressed the
antigen-induced [Ca
2+]i elevation and the antigen-enhanced mRNA expression of TNF-α, IL-4, and IL-13. The transcriptome and
real-time PCR analyses revealed that ZF greatly decreased the antigen-enhanced expression level of sphingosine kinase 1 (Sphk1),
which plays a key role in the FcεRI-mediated immune responses in mast cells. Furthermore, ZF inhibited allergic symptoms in
an ovalbumin-caused murine FA model and decreased the number of inﬁltrating mucosal mast cells and the enhanced mRNA
expression levels of IL-4 and Sphk1 in the FA mice colons. These results indicate that ZF suppresses mucosal mast cell activities
mainly through Sphk1-dependent mechanism, and ZF is utilized for the development of a novel, potent anti-FA agent.
1.Introduction
Food allergy (FA) is an abnormal immunologic reaction to
food proteins. The prevalence of FA in children is estimated
to be approximately 4% to 10%. The greatest prevalence is
in the ﬁrst few years of life, and a gradual decrease occurs
during the ﬁrst decade as tolerance develops [1], although
some peanut allergy is rarely outgrown [2].
Althoughtheunderlyingpathogenicmechanismsoffood
allergy are not well understood, it is well known that mast
cells play central roles in the pathogenesis of various allergic
disorders.Theactivationofmastcellsleadstothesecretionof
various proteases, autacoids, growth factors, cytokines, and
chemokines [3, 4]. Two distinct populations of mast cells
exist: mucosal mast cells and connective-tissue mast cells.
Considerable evidence has demonstrated that mucosal mast
cells are morphologically, biochemically, and functionally
distinct from connective-tissue mast cells [5]. We have
previously demonstrated that the number of mucosal mast
cells in the colons of our ovalbumin-induced FA model mice
is increased [6], and that mucosal mast cells play important
roles in the allergic reaction in our FA model [7]. At present,
connective tissue mast cell stabilizers (tranilast, ketotifen,
and cromolyn) are frequently used for the treatment of
v a r i o u sa l l e r g i cd i s o r d e r sb e s i d e sF A .T h e s ea g e n t sh a v en o
eﬀect on mucosal mast cells [8]. Until now, there has been
little information on the inhibitory agents against mucosal
mast cell activation [8–11].
Currently, no therapeutic drugs for FA have been devel-
oped, and the avoidance of food antigens is the central2 Evidence-Based Complementary and Alternative Medicine
therapy that is used to prevent further reactions in FA
patients. Consequently, novel approaches are being explored
to develop innovative medicines. Speciﬁcally, traditional
medicines have proven to be a potential source for the
development of new therapeutic medicines [12]. Many
herbalmedicinesareusedastraditionalremediesfortreating
various diseases, which include allergic diseases, particularly
in Asian countries. Li et al. [12–14] have reported that
Chinese herbal medicines, food allergy herbal formula-1
(FAHF-1) and FAHF-2, ameliorate peanut-induced anaphy-
laxis in a murine FA model. Furthermore, FAHF-2 reduces
allergen-stimulated basophil activation, hyperreleasability,
andpercentagesofcirculatingbasophilsina6-monthclinical
trial for patients with food allergy [15]. In addition, we have
demonstrated that kakkonto, a traditional medicine that is
frequently used in Japan and China, alleviates the allergic
symptoms that are induced by food antigens [6]. Therefore,
to address the development of new therapeutic medicines
for FA, we screened 80 medicinal herbs that are frequently
used in Japan using rat-basophilic-leukemia (RBL-) 2H3
mast-like cells. Of the 80 medicinal herbs, the water extracts
of Arecae Semen, Cinnamoni Cortex, Curcumae Rhizoma,
Rhei Rhizoma, and Zanthoxyli Fructus signiﬁcantly inhibited
antigen-induced degranulation. Furthermore, we found that
Zanthoxyli Fructus water extract exhibited the most potent
inhibitory eﬀect in a preliminary study that used our FA
model.
Zanthoxylum piperitum De Candolle (ZPDC), a decid-
uous shrub, is distributed in Japan, China, and Korea. The
fruit of ZPDC, which is called Shan-Jiao in Chinese and
Sansho in Japanese, is utilized as a spice and a traditional
herbal medicine in Asia. It has been reported that glyco-
proteins in the Zanthoxyli Fructus have anti-inﬂammatory
properties [16]. However, it remains still unclear whether
ZanthoxyliFructusplaysasuppressiveeﬀectontheactivation
of mucosal mast cells and the development of FA.
In this study, we investigated the eﬀect of the water
extract of the fruit of ZPDC (ZF) on mucosal mast cells,
explored the underlying mechanism of the pharmacological
eﬀects, and demonstrated for the ﬁrst time that ZF inhibited
the activation of mucosal mast cells in vitro and in vivo
primarilythroughthesuppressionofantigen-inducedsphin-
gosine kinase 1 (Sphk1) gene expression. Therefore, ZF may
serve as a leading candidate for the development of novel
anti-FA agents.
2.MaterialsandMethods
2.1. Animals. Male BALB/c mice (5 weeks old) were pur-
chased from Japan SLC Inc. (Shizuoka, Japan). All mice were
housedwithfreeaccesstofoodandwaterintheexperimental
animal facility at the University of Toyama. All of the animal
care procedures and experiments were approved by the
Animal Experiment Committee at the University of Toyama
(Authorization no. S-2009 INM-9).
2.2. Reagents. Recombinant murine SCF, recombinant
murine IL-3, recombinant murine IL-9, and TGF-β1w e r e
purchased from Peprotech (London, UK). N, N-dimeth-
ylsphingosine (DMS), 3-O-caﬀeoylquinic acid, catechin,
hyperﬁne, and epicatechin were purchased from Cayman
Chemical (Ann Arbor, MI, USA). Limonene, A23187,
ovalbumin (OVA, faction V), propidium iodide (PI), and
aluminum hydroxide gel were purchased from Sigma (St.
Louis, MO, USA). Cyclosporin A, W-7, and KN-93 were
purchased from Calbiochem (San Diego, CA, USA). RPMI-
1640 medium was purchased from Wako (Osaka, Japan).
Antidinitrophenyl (DNP) IgE was purchased from Yamasa
(Tokyo, Japan). Fura-2 AM and Fluo-3 AM were purchased
from Dojindo (Kumamoto, Japan). Mouse GeneChip Gene
1.0 ST Array was purchased from Aﬀymetrix (Santa Clara,
CA, USA). Antiserum against mouse mucosal mast cell
protease (mMCP)-1 was purchased from Moredun Scien-
tiﬁc (Penicuik, UK). Hydroxy-α-sanshool was provided by
Tsumura Co. (Tokyo, Japan). Sepasol Super was purchased
from Nacalai Tesque (Kyoto, Japan). RNeasy Plus Micro was
procured from Qiagen (Hilden, Germany).
2.3. Preparation of Extracts. The water extracts of medicinal
herbs were provided by the Joint Usage/Research Center
for Science-Based Natural Medicine, Institute of Natural
Medicine, University of Toyama and the Knowledge Cluster
Initiative Program (Second Stage) from the Ministry of
Education, Culture, Sports, Science and Technology of
Japan. Brieﬂy, crude herbs (45.0g) were extracted with
900mL of hot water under reﬂux conditions. Following
ﬁltration through a cotton-inserted funnel, the extract
was lyophilized for 2 days. The yield of ZF was 19.8%
(w/w). Quality control of ZF was performed by an LC-MS
analysis using a LC-IT-TOF mass spectrometer equipped
with an ESI interface (Shimadzu LC-IT-TOF MS ESI,
Shimadzu Scientiﬁc Instruments, Kyoto, Japan). The mass
spectrometry data that were obtained from the extract
were registered in the Wakan-Yaku DataBase system at the
Institute of Natural Medicine of the University of Toyama
(http://wakandb.u-toyama.ac.jp/wiki/LCMS:Zanthoxyli
Fructus/10025907).
2.4.CellCulture. TheRBL-2H3cellswerekindlyprovidedby
Dr. Hidetaka Yakura (Tokyo Metropolitan Institute for Neu-
roscience, Tokyo, Japan) and maintained in complete RPMI-
1640 medium. The mucosal-type murine bone marrow-
derived mast cells (mBMMCs) were prepared from the
femurs of BALB/c mice as described previously [9, 17].
Brieﬂy, the bone marrow cells were cultured in complete
RPMI-1640mediumthatcontained40ng/mLSCF,20ng/mL
IL-3, 5ng/mL IL-9, and 1ng/mL TGF-β1f o r4w e e k s .T h e
mast cell purity was examined by ﬂow cytometry (FACS
Calibur; Becton Dickinson, Franklin Lakes, NJ, USA), and
more than 98% of the nonadherent cells were high-aﬃnity
IgE receptor (FcεRI) and c-kit positive (data not shown).
2.5. Activation of RBL-2H3 Cells and mBMMCs. The acti-
vation of RBL-2H3 cells and mBMMCs was performed as
previously described [9]. Brieﬂy, the RBL-2H3 cells and
mBMMCs were sensitized with 0.5μg/mL and 1.5μg/mLEvidence-Based Complementary and Alternative Medicine 3
anti-DNP IgE for 24h and 6h, respectively, at 37◦C. The
cellswerewashedandincubatedwithmedicinalherbextracts
or test drugs. After 30min, the cells were stimulated with
100ng/mL DNP-BSA at 37◦C for 1h; the samples were
then centrifuged, and the supernatants and cell pellets were
collected for use in the degranulation assay, real-time PCR
analysis, and transcriptome analysis. In the experiments
that utilized calcium ionophore, the RBL-2H3 cells and
mBMMCs were incubated with ZF or test drugs for 30min,
and the cells were then stimulated with 25μMc a l c i u m
ionophore A23187 for 30min.
2.6. Degranulation Assay. The degree of degranulation was
assessed by measuring β-hexosaminidase release, which has
been previously described [9]. The extent of degranulation
was calculated by dividing the absorbance of the supernatant
by the sum of absorbances of the supernatant and cell lysate.
2.7. Viability Analysis by PI Staining. The mBMMCs that
were pretreated with ZF for 90min at 37◦C in a humidiﬁed
5% CO2 atmosphere were washed twice with ﬂuorescence-
activated cell sorter (FACS) buﬀer (1% BSA and 0.2% NaN3
in PBS), and the cells were then resuspended in FACS
buﬀer in polystyrene round-bottom tubes. After staining
with 2μg/mL PI, the viability of the cells was examined using
the FACS Calibur system.
2.8. Intracellular Calcium Measurement. Cross-linking of
FcεRI by antigens induces mast cell activation, which leads
to the elevation of the intracellular calcium concentration
([Ca2+]i) prior to the exocytosis of granules and cytokines
[4]. The measurement of [Ca2+]i was performed as pre-
viously described [8]. Brieﬂy, the sensitized mast cells
were loaded with 5μM Fura-2 AM in loading buﬀer. The
ﬂuorescence was measured at 340 and 380nm using a
model F-4500 ﬂuorescence spectrophotometer intracellular
Ca2+ measurement system (Hitachi, Tokyo, Japan), and the
background-corrected 340:380 ratio was calibrated.
For an experiment with calcium ionophore A23187,
the calcium imaging experiments were performed using
the AQUACOSMOS IMAGO CCD camera-based system
(HAMAMATSU, C7773, Hamamatsu, Japan). The cells were
loaded with 10μM Fluo-3 AM in loading buﬀer for 30min;
they were washed once and were then monitored for 4min at
310nm.
2.9. Transcriptome Analyses. The global gene expression
analysis was performed using an Aﬀymetrix Mouse
GeneChip Gene 1.0 ST Array that was spotted with 28,853
p r o b es e t s .T h et o t a lR N Aw a si s o l a t e df r o mm B M M C su s i n g
the RNeasy Plus Micro kit according to the manufacturer’s
instructions, and the mRNA for the array hybridization was
prepared as described in the GeneChip Expression Technical
Manual. The data were ﬁrst analyzed using the GeneChip
Analysis Suite Software (Aﬀymetrix) and were further
analyzed using Gene-Spring software (Silicon Genetics, CA,
USA) to identify the signiﬁcant genes. The fold-change log2
ratio is the change in the expression level of a transcript that
is expressed as the log2 ratio (the fold-change log2 ratio of 1
and −1a r ee q u a lt oaf o l dc h a n g eo f2a n d0 . 5 ,r e s p . ) .
2.10.AllergicDiarrheaInductioninaMurineFAModel. Male
BALB/c mice were sensitized twice at a 2-week interval by
intraperitoneal injection with 50μg of OVA in the presence
of 1.3mg of aluminum hydroxide gel as an adjuvant. Two
weeks after systemic priming, the mice were repeatedly given
50mg of OVA that was dissolved in 0.3mL of water using
intragastric feeding needles every other day. Diarrhea was
assessed by visually monitoring the mice for up to 1h
following the intragastric challenge. For treatment with ZF
(32, 100 and 320mg/kg body weight) or DMS (1mg/kg body
weight) in the FA model, the agents were orally administered
to the mice each day throughout the period of oral OVA
administration, and they were administered 1h prior to the
OVA challenge.
For histological analysis, the proximal colon was excised
1h after the ﬁfth or sixth oral OVA challenge and stained
using antibodies against mMCP-1 according to the proce-
dure that was described previously [6].
2.11. Real-Time PCR. Total RNA was extracted from the
proximal colon using the Sepasol Super according to the
manufacturer’s instructions. Quantitative real-time PCR was
performed as previously described [6]. The following primer
pairs were used: IL-4 forward: 5 -GGT CTC AAC CCC CAG
CTA GT-3  and reverse: 5 -GCC GAT GAT CTC TCT CAA
GTG AT-3 ;I L - 1 3f o r w a r d :5  -GGA TAT TGC ATG GCC
TCT GTA AC-3  and reverse: 5 -AAC AGT TGC TTT GTG
TAG CTG A-3 ;T N F - α forward: 5 -AAG CCT GTA GCC
CAC GTCGTA-3  and reverse:5 -GGC ACC ACT AGT TGG
TTG TCT TTG-3 ; Sphk1 forward: 5 -AGT CGC CAG ACA
CCC TCC TG-3  and reverse: 5 -CCT CGA GGG CAT TCT
GGT TCC-3 ; GAPDH forward: 5 -TGA CCA CAG TCC
ATG CCA TC-3  and reverse: 5 -GAC GGA CAC ATT GGG
GGT AG-3 . The target mRNA was normalized to GAPDH
mRNA as an internal control in each sample. Results were
expressed as the relative ratio to the control group average (1
in vehicle-treated mBMMCs without DNP-BSA stimulation
or the proximal colons of vehicle-treated FA mice).
2.12. Statistical Analysis. Data are presented as the mean ±
SD. The statistical comparisons were performed using
Student’s t-test and repeated measures one-way ANOVA
followed by post hoc Dunnett’s test or chi-square test with
SPSS software (version 19, IBM, Somers, NY, USA). Values
of P<0.05 were considered signiﬁcant.
3. Results
3.1. Water Extracts of Arecae Semen, Cinnamoni Cortex,
Curcumae Rhizoma, Rhei Rhizoma, and Zanthoxyli Fructus
Inhibit Antigen-Stimulated Degranulation in RBL-2H3 Cells.
Eighty medicinal herb extracts were screened for their
inhibitory eﬀect on DNP-BSA-stimulated degranulation in
RBL-2H3 cells. The water extracts of Arecae Semen, Cin-
namoni Cortex, Curcumae Rhizoma, Rhei Rhizoma, and4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Inhibitory eﬀe c to ft h ew a t e re x t r a c t so fArecae Semen, Cinnamoni Cortex, Curcumae Rhizoma, Rhei Rhizoma, and Zanthoxyli
Fructus on degranulation that was induced by antigens in the RBL-2H3 cells. (a) The time scheme for the degranulation assay. (b) RBL-
2H3 cells that were sensitized with 0.5μg/mL anti-DNP IgE (24h) were incubated with herbal medicine extracts for 30min. The cells were
stimulated with (ﬁlled) or without (open) 100ng/mL DNP-BSA for 1h, and β-hexosaminidase release was determined. (c) The inhibitory
eﬀect of antiallergic drugs (10μM) on DNP-BSA-induced degranulation was examined. The data are expressed as the mean ± SD (n = 3;
B, C). ∗P<0.05 compared with the vehicle (b, c). (d) The eﬀect of ZF (0.32mg/mL) treatment on the increase of [Ca2+]i that was induced
DNP-BSA. The RBL-2H3 cells that were sensitized with IgE were labeled with Fura-2 AM and treated with ZF or vehicle for 30min. The
Ca2+-mobilization was determined after stimulation with DNP-BSA using F4500. The data are representative of at least three independent
experiments.
Zanthoxyli Fructus (≥0.1mg/mL) inhibited the stimulated
degranulation in a dose-dependent manner (Figure 1(b)).
In contrast, none of the clinically available antiallergic drugs
(10μM), cromolyn, ketotifen and tranilast, which are known
to be connective tissue mast cell stabilizers, inhibited the
degranulation (Figure 1(c)).
In an in vivo preliminary study, ZF (500mg/kg body
weight) displayed the most potent inhibitory eﬀect of the
ﬁve extracts that were examined in our FA model (data not
shown). Therefore, we selected ZF for further study.
The mobilization of intracellular calcium is essential for
degranulation and cytokine production in mast cells. As
shown in Figure 1(d), ZF attenuated the DNP-BSA-induced
[Ca2+]i elevation in RBL-2H3 cells. In addition, ZF did
not alter FcεRI surface expression in RBL-2H3 cells (the
expressionwas96.3%ofthatofnontreatedRBL-2H3),which
indicates that ZF inhibits signals downstream of FcεRI cross-
linking.
Additionally, we examined the inhibitory eﬀects of
ZF constituents hydroxy-α-sanshool, limonene, 3-O-caffe-
oylquinic acid, catechin, hyperine, and epicatechin (1, 10,
and 100μM). Individually, hydroxyl-α-sanshool, epicate-
chin, catechin, and hyperine slightly attenuated the degranu-
lation only at the highest concentration (100μM) (Table 1).Evidence-Based Complementary and Alternative Medicine 5
Table 1: The inhibitory activity of ZF components (100μM)
on antigen-induced degranulation. The data are expressed as the
mean ± SD (n = 3).
Compounds Inhibition of degranulation (%)
Hydroxy-α-sanshool 21.1 ±11.9
Epicatechin 15.7 ± 7.1
Catechin 13.0 ± 4.8
Hyperoside 7.7 ±5.2
Limonene −11.4 ±9.9
3-O-Caﬀeoylqunic acid −13.3 ±7.7
3.2. ZF Inhibits Antigen-Induced Activities in mBMMCs. In
a dose-dependent manner, ZF signiﬁcantly inhibited the
degranulation of the mBMMCs that were induced with
DNP-BSA (Figure 2(b)) without detectably aﬀecting the
viability of the mBMMCs (Figure 2(c)). As shown in
Figure 2(d), mRNA expression of TNF-α, IL-4, and IL-13
was extremely enhanced by DNP-BSA. ZF (0.32mg/mL)
signiﬁcantly suppressed the increased expression of TNF-
α, IL-4, and IL-13. In contrast, the expression of these
genes was not aﬀected by ZF in the mBMMCs that were
not stimulated with DNP-BSA (unactivated mBMMCs).
In addition, ZF attenuated the DNP-BSA-induced [Ca2+]i
increases (Figure 2(e)).
3.3. ZF Reduces Sphk1 mRNA Expression in Antigen-
Stimulated mBMMCs. To investigate the pharmacological
mechanism that is responsible for the inhibitory eﬀect of
ZF on mBMMCs, we examined the global mRNA expres-
sion proﬁles of normal mBMMCs, DNP-BSA-stimulated
mBMMCs (activated mBMMCs), and ZF-pretreated acti-
vated mBMMCs (ZF mBMMCs) using an Aﬀymetrix Mouse
GeneChip Array. The expression levels of 49 genes were
elevated >2-fold higher in the activated mBMMCs when
compared to the normal mBMMCs, and they were decreased
by >50% in the ZF mBMMCs when compared to the acti-
vated mBMMCs. In contrast, the expression levels of 6 genes
were decreased by >50% in the activated mBMMCs when
compared to the normal mBMMCs, and they were elevated
>2-fold higher in the ZF mBMMCs when compared to the
activated mBMMCs (Table 2). Interestingly, the expression
of Sphk1, which plays an important role in antigen-induced
degranulation [18–20], was induced approximately 5.7-
fold in the activated mBMMCs when compared with the
normal mBMMCs. The ZF pretreatment greatly reduced
the expression of Sphk1 to 16% of the expression level in
the activated mBMMCs, whereas the DNP-BSA stimulation
did not alter Sphk2 expression when compared with that
in the normal mBMMCs (1.35-fold relative to the normal
mBMMCs).
Furthermore, we quantitatively assessed the suppressive
eﬀect of ZF on Sphk1 mRNA expression using real-time
PCR. As shown in Figure 3, the Sphk1 mRNA expression
level in the activated mBMMCs was markedly enhanced
10.2-fold relative to the unactivated mBMMCs. The induc-
tion was dramatically reduced to approximately 20% in the
ZF mBMMCs. In contrast, the Sphk1 mRNA expression was
not aﬀected by ZF in the unactivated mBMMCs.
To clarify the involvement of Sphk1 in the degranulation
of mucosal mast cells, we examined the eﬀect of DMS,
which is a speciﬁc Sphk inhibitor, on the antigen-induced
degranulation in mBMMCs. DMS (10μM) signiﬁcantly
suppressed the release of β-hexosaminidase (Figure 4).
3.4. ZF Inhibits Calcium Ionophore-Induced Degranulation.
To investigate the pharmacological proﬁle of ZF on mucosal
mast cell activation, we examined the eﬀect of ZF on the
[Ca2+]i increases and β-hexosaminidase release induced by
the calcium ionophore A23187. The ZF treatment dimin-
ished the [Ca2+]i increases in RBL-2H3 cells (Figure 5(b)).
In addition, ZF signiﬁcantly inhibited A23187-induced
degranulationinbothRBL-2H3cellsandmBMMCs(Figures
5(c), 5(d)). Moreover, the calcineurin inhibitor cyclosporin
A( 1 μM), the calmodulin antagonist W-7 (32μM), and
the Ca2+/calmodulin-dependent protein kinase II inhibitor
KN-93 (32μM) inhibited A23187-induced degranulation in
mBMMCs to a similar extent as ZF, which indicates that
A23187 induces degranulation via both calcineurin- and
calmodulin-dependentpathwaysinmBMMCs(Figure5(d)).
In contrast, DMS (10μM) did not aﬀect A23187-induced
degranulation in mBMMCs (Figure 5(d)). Furthermore,
when the mBMMCs were stimulated with the calcium
ionophore A23187 (instead of anti-DNP IgE and DNP-BSA)
and examined with the Aﬀymetrix Mouse Genechip Array,
the expression of Sphk1 was not altered (data not shown).
3.5. ZF Suppresses Allergic Symptoms in the Murine FA Model.
In OVA-challenged mice (FA mice), allergic diarrhea began
to occur after the third oral OVA challenge (Figure 6(a)).
The administration of ZF (320mg/kg) signiﬁcantly reduced
the incidence of OVA-induced diarrhea, and the incidence
of diarrhea was decreased to approximately 40% after the
sixth OVA challenge. As shown in Figure 6(b), the admin-
istration of DMS (1mg/kg) likewise signiﬁcantly reduced the
incidence of diarrhea. Furthermore, the number of mucosal
mastcellsthatwereobservedbyimmunohistochemistrywith
mMCP-1 antibody dramatically increased in the proximal
colons of FA mice compared with the number in normal
mice, which is consistent with our previous paper [6]. ZF
and DMS dramatically decreased the number of inﬁltrating
mucosal mast cells in the proximal colons of the FA mice
(Figure 6(c)). In addition, as shown in Figure 6(d),Z F
repressed the mRNA expression of IL-4 and Sphk1 in the
proximal colons of the FA mice.
4. Discussion
In this study, we have demonstrated in vitro and in vivo
that ZF inhibited FcεRI cross-linking-induced mucosal mast
cell activation; this inhibition was primarily achieved via
the suppression of Sphk1 mRNA expression, and Sphk1
plays a key role in FcεRI-mediated immune responses
in mucosal mast cells. Furthermore, ZF suppressed the
calcium ionophore-induced degranulation, which could not6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: The eﬀect of ZF (0.32mg/mL) on degranulation, cytokine levels, and [Ca2+]i elevation of the mBMMCs that were stimulated with
DNP-BSA. (a) The time scheme for the degranulation assay, real-time PCR analysis, and transcriptome analysis. (b) The mBMMCs that
were sensitized with 1.5μg/mL anti-DNP IgE (6h) were incubated with ZF for 30min. The cells were stimulated with (ﬁlled) or without
(open) DNP-BSA (1h), and the β-hexosaminidase release was determined. (c) The mBMMCs were pretreated with ZF (0.32mg/mL) for
90min and stained with PI; the viability was analyzed using the FACS Calibur system. (d) The sensitized mBMMCs were incubated with
ZF (0.32mg/mL) or vehicle for 30min and then stimulated with DNP-BSA for 1h, and the total RNA was extracted. The mRNA levels
of TNF-α, IL-4, and IL-13 were analyzed by real-time PCR. The results are expressed as the relative ratio to the vehicle-treated mBMMCs
without DNP-BSA stimulation. The data are expressed as the mean ± SD (n = 3–4; b, c, d). #P<0.05 compared with DNP-BSA (−) (d),
∗P<0.05 compared with the vehicle (b, d). (e) The sensitized mBMMCs were labeled with Fura-2 AM for 30min and incubated with ZF
or vehicle for 30min. Ca2+-mobilization was determined following stimulation with DNP-BSA. The data are representative of at least three
independent experiments.Evidence-Based Complementary and Alternative Medicine 7
Table 2: List of genes selected by microarray analysis. The fold-change log2 ratio was calculated as the log2 ratio of the expression level in
the activated mBMMCs compared to the expression in the normal mBMMCs or as the log2 ratio of the expression level in the ZF mBMMCs
compared to that in the activated mBMMCs. (a) Upregulation (>2 fold) of genes by DNP-BSA stimulation and downregulation (>2 fold)
after ZF pretreatment. (b) Downregulation (>2 fold) of genes by DNP-BSA stimulation and upregulation (>2 fold) after ZF pretreatment.
Gene name Gene description
Fold-change log2 ratio
IgE + DNP/
Normal
ZF/
IgE + DNP
(a)
Tnip3 TNFAIP3 interacting protein 3 4.47 −3.36
Sphk1 Sphingosine kinase 1 2.50 −2.65
Chac1 ChaC, cation transport regulator-like 1 (E. coli)1 . 8 0 −2.40
Trib1 Tribbles homolog 1 (Drosophila)3 . 2 1 −2.39
Uhrf1bp1l UHRF1 (ICBP90) binding protein 1-like 1.82 −2.23
Car2 Carbonic anhydrase 2 2.16 −1.86
Socs3 Suppressor of cytokine signaling 3 1.89 −1.82
Sema7a Sema domain, immunoglobulin domain (Ig), and GPI
membrane anchor, (semaphorin) 7A 2.25 −1.77
Fermt2 Fermitin family homolog 2 (Drosophila)2 . 8 1 −1.75
Zfp57 Zinc ﬁnger protein 57 1.90 −1.71
Klf9|Gm9971 Kruppel-like factor 9 | predicted gene 9971 1.42 −1.68
Mustn1 Musculoskeletal, embryonic nuclear protein 1 1.57 −1.64
Tnfsf8 Tumor necrosis factor (ligand) superfamily, member 8 2.48 −1.64
Gimap5 GTPase, IMAP family member 5 1.41 −1.61
Dusp18 Dual-speciﬁcity phosphatase 18 1.08 −1.58
Slco4a1 Solute carrier organic anion transporter family, member 4a1 2.25 −1.57
Fhl2 Four and a half LIM domains 2 1.06 −1.56
Spry2 Sprouty homolog 2 (Drosophila)2 . 6 4 −1.53
A630033H20Rik RIKEN cDNA A630033H20 gene 2.34 −1.52
Zc3h12a Zinc ﬁnger CCCH type containing 12A 1.70 −1.51
Nfkbia Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha 1.92 −1.50
Il2 Interleukin 2 1.91 −1.50
Zc3h12c Zinc ﬁnger CCCH type containing 12C 2.28 −1.47
Marcksl1 MARCKS-like 1 2.88 −1.42
Hbegf Heparin-binding EGF-like growth factor 4.90 −1.41
Csf2 Colony stimulating factor 2 (granulocyte macrophage) 5.30 −1.41
Erf Ets2 repressor factor 2.10 −1.40
Kcnk5 Potassium channel, subfamily K, member 5 1.13 −1.38
Mmd Monocyte to macrophage diﬀerentiation associated 2.05 −1.37
Phlda1 Pleckstrin homology-like domain, family A, member 1 3.10 −1.32
Zc3h12c Zinc ﬁnger CCCH type containing 12C 2.26 −1.31
Rilpl2 Rab interacting lysosomal protein-like 2 1.48 −1.31
Faah Fatty acid amide hydrolase 2.35 −1.29
Fst|Thrap3 Follistatin | thyroid-hormone-receptor-associated protein 3 1.67 −1.19
Insig1 Insulin-induced gene 1 1.65 −1.19
Spry1 Sprouty homolog 1 (Drosophila)4 . 3 6 −1.19
Pde12 Phosphodiesterase 12 1.29 −1.19
Rc3h1 RING CCCH (C3H) domains 1 1.13 −1.18
Dusp2 Dual-speciﬁcity phosphatase 2 2.15 −1.158 Evidence-Based Complementary and Alternative Medicine
Table 2: Continued.
Gene name Gene description
Fold-change log2 ratio
IgE + DNP/
Normal
ZF/
IgE + DNP
F3 Coagulation factor III 1.16 −1.13
Eda2r Ectodysplasin A2 receptor 1.65 −1.11
Prrg4 Proline-rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 1.95 −1.11
Traf6 TNF receptor-associated factor 6 1.03 −1.08
Peli1 Pellino 1 1.48 −1.07
Cxcl2 Chemokine (C-X-C motif) ligand 2 3.91 −1.04
Ptger4 Prostaglandin E receptor 4 (subtype EP4) 1.06 −1.03
Siah2 Seven in absentia 2 1.20 −1.02
Chka Choline kinase alpha 1.58 −1.01
Ehd4 EH-domain containing 4 1.10 −1.01
(b)
Cbfa2t3 Core-binding factor, runt domain, alpha subunit 2, translocated
to 3 (human)
−1.59 1.71
ATP6|Gm10925 ATP synthase F0 subunit 6 | predicted gene 10925 −1.20 2.01
Nynrin NYN domain and retroviral integrase containing −1.11 1.00
Hist1h1c Histone cluster 1, H1c −1.01 1.15
Arrdc3 Arrestin domain containing 3 −1.10 1.36
Gﬁ1b Growth-factor-independent 1B −1.52 1.40
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Figure 3: The eﬀect of ZF (0.32mg/mL) on the mRNA expression
levels of Sphk1. The sensitized mBMMCs were incubated with ZF
or vehicle for 30min and were stimulated with (ﬁlled) or without
(open) DNP-BSA. The mRNA levels of Sphk1 were analyzed by
real-time PCR. The results are expressed as the relative ratio to the
vehicle-treated mBMMCs without DNP-BSA stimulation. The data
are expressed as the mean ± SD (n = 3). #P<0.05 compared with
DNP-BSA (−), ∗P<0.05 compared with the vehicle.
be suppressed by an Sphk1 inhibitor. Therefore, the present
results suggest that ZF could be utilized for the development
of a novel, potent anti-FA agent.
4.1. Inhibitory Eﬀect of ZF on Antigen-Induced Mucosal Mast
Cell Activation In Vitro. Mast cells are key players in various
allergic responses, and mucosal mast cells have been shown
to play pivotal roles in gastrointestinal hypersensitivity [6–
8]. They respond to both IgE-dependent (antigen) and IgE-
independent(suchasbacterialtoxinsandneurotransmitters)
stimulation and release a wide variety of bioactive mediators
into adjacent tissues [21].
Although the available mast cell stabilizers did not aﬀect
degranulation in RBL-2H3 cells as well as mBMMCs, ZF
inhibited antigen-induced degranulation in mBMMCs and
RBL-2H3 cells. Mast cells generate and release proinﬂam-
matory and Th2-related cytokines, including TNF-α,I L -
4, and IL-13, in response to various stimuli [3]. TNF-α is
largely responsible for allergic inﬂammation, and IL-4, and
IL-13 are necessary for the development of Th2 immune
responses and the induction of IgE class switching [4].
ZF signiﬁcantly inhibited the mRNA expression of these
cytokines in the mBMMCs. Lee et al. have recently reported
in a connective-tissue mast cell model that glycoproteins
in the Zanthoxyli Fructus have an inhibitory eﬀect on the
release of histamine and β-hexosaminidase in the compound
48/80-treated human mast cells [16]. In mucosal-type mast
cells, ZF displayed potent inhibitory eﬀects on degranulation
andproinﬂammatory-andTh2-relatedcytokineproduction,
and ZF suppressed the increase of [Ca2+]i that was triggered
by antigens in RBL-2H3 cells and mBMMCs. These resultsEvidence-Based Complementary and Alternative Medicine 9
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Figure 4: The inhibitory eﬀect of DMS on the degranulation
of mBMMCs that were induced by DNP-BSA. The sensitized
mBMMCs were pretreated with 10μM DMS for 30min prior to
DNP-BSA stimulation. The data are expressed as the mean ± SD
(n = 4). ∗P<0.05 compared with the vehicle.
suggest that ZF inactivates mucosal mast cells by suppressing
[Ca2+]i.
Individually, the constituents of ZF that were tested here
did not signiﬁcantly inhibit antigen-induced degranulation
in RBL-2H3 cells. One possible explanation for this result is
that the inhibitory eﬀect of ZF on mast cells is related to the
additive/synergistic eﬀects of these and other constituents in
ZF. However, further studies on the active constituents of ZF
will be required to fully explain the inhibitory eﬀect of ZF.
4.2. Suppression of Sphk1 mRNA Expression by ZF and
the Pathophysiological Role of Sphk1 in Mucosal Mast Cells
In Vitro. To investigate the mechanism underlying the
inhibitory eﬀect of ZF on mucosal mast cell activation,
we performed global transcriptional proﬁling of mBMMCs
by DNA microarray. We found that the expression level
of Sphk1 mRNA was increased in the antigen-stimulated
mBMMCs and decreased following ZF treatment. The
stimulation of mast cells by antigens induces two mam-
malian Sphks (Sphk1 and Sphk2) to generate sphingosine
1-phosphate (S1P). S1P has been demonstrated to function
intracellularly as a second messenger for the regulation
of cell survival, cell proliferation, and intracellular Ca2+
mobilization [22, 23]. A recent study shows that Sphk1
but not Sphk2 plays a critical role in the antigen-induced
[Ca2+]i elevation, degranulation, and cytokine production in
connective-tissue type BMMCs [18]. Furthermore, antigen-
induced degranulation is suppressed by the deletion of
Sphk1 in RBL-2H3 cells and human mast cells [19, 20].
In the present study, our results revealed that the Sphk
inhibitor DMS signiﬁcantly suppressed antigen-induced
degranulation in mBMMCs. Thus, Sphk1 is a determinant
of the responsiveness to the cross-linking of FcεRI with
a n t i g e ni nm u c o s a lm a s tc e l l sa sw e l la sc o n n e c t i v e - t i s s u e
mast cells. Furthermore, ZF decreased the antigen-induced
elevation of [Ca2+]i through the suppression of antigen-
induced enhancement of Sphk1 mRNA expression in vitro.
Therefore,Sphk1maybeanewtherapeutictargetfordiseases
that are caused by both types of mast cells; ZF may provide
an opportunity to develop a novel therapeutic strategy for
the treatment of FA. To date, Sphk inhibitor DMS and
the S1P receptor modulator FYT720 have been developed,
while there is no information about drugs that suppress the
expression of Sphk1. Taken together, these data suggest that
ZF may provide a prototype for therapeutic drugs for the
treatment of various allergic diseases, particularly FA.
4.3. Sphk1-Independent Mechanism Underlying the Inhibitory
Eﬀect of ZF on Mucosal Mast Cells In Vitro. We found that
the calcium ionophore A23187 did not alter Sphk1 mRNA
expression in mBMMCs using a transcriptome analysis
(our unpublished data), and DMS did not inhibit A23187-
induced degranulation in mBMMCs, which is consistent
with previous reports. Both the DMS treatment and Sphk1
knock-down fail to aﬀect ionomycin-induced degranulation
inRBL-2H3cellsorconnective-tissue-typeBMMCs[18,19].
Taken together, these data suggest that Sphk1 acts at the
upstream of the calcium signaling pathway in mast cells.
In contrast, ZF suppressed A23187-induced degranulation
and [Ca2+]i elevation in mucosal-type mast cells. Further-
more, in mBMMCs, the calcineurin inhibitor cyclosporin A,
the calmodulin antagonist W-7, and the Ca2+/calmodulin-
dependent protein kinase II inhibitor KN-93 suppressed
A23187-induced degranulation to a similar extent as ZF,
which is consistent with previous reports [24, 25]. These
results indicate that A23187 induces degranulation via both
calcineurin- and calmodulin-dependent pathways in mast
cells. Taken together, these data suggest that ZF suppresses
the activation of mast cells by blocking calcium inﬂux
with or without inhibiting calcineurin- and calmodulin-
dependent pathways in mast cells. Therefore, our results
indicate that ZF suppresses not only antigen-induced Sphk1
expression, but also critical molecules in the calcium inﬂux
pathway. Additional studies will be required to understand
this inhibitory mechanism.
4.4. Therapeutic Eﬀect of ZF and Inhibition of the Sphk1
P a t h w a yi nt h eM u r i n eF AM o d e lI nV i v o .The oral admin-
istration of ZF suppressed the occurrence of allergic diarrhea
and decreased the number of colonic mucosal mast cells in
our FA model. We showed that the administration of ZF
downregulated the mRNA expression of IL-4 in the proximal
colons of FA mice, which suggests that ZF suppressed the
Th2-polarized cytokine proﬁle in the proximal colons of
FA mice. In addition, ZF inhibited the expression of Sphk1
mRNA in the proximal colons of FA mice. Furthermore,
in the present study, DMS likewise reduced the occurrence10 Evidence-Based Complementary and Alternative Medicine
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Figure 5: The eﬀect of ZF (0.32mg/mL) treatment on A23187-induced [Ca2+]i elevation and degranulation. (a) The time scheme for the
degranulation assay. (b) RBL-2H3 cells were labeled with Fluo-3 AM and incubated with ZF or vehicle for 30min. The cells were stimulated
with 25μM A23187 and monitored by calcium imaging. The data are representative of at least three independent experiments. (c) The RBL-
2H3 cells were incubated with ZF or vehicle for 30min, the cells were stimulated with (ﬁlled) or without (open) A23187 for 30min, and
β-hexosaminidase release was determined. (d) The mBMMCs were incubated with ZF (0.32mg/mL), DMS (10μM), cyclosporin A (1μM),
W-7 (32 μM), KN-93 (32μM), or vehicle for 30min, and the cells were stimulated with 25μM A23187 for 30min. β-hexosaminidase release
was determined. The data are expressed as the mean ± SD (n = 4; c, d). ∗P<0.05 compared with the vehicle (c, d).
of allergic diarrhea and the number of mucosal mast
cells in the proximal colons of FA mice. Similarly, DMS
exerts an inhibitory eﬀect on the OVA-induced pulmonary
inﬂammatory responses in a murine model of allergic
asthma [26]. It is generally accepted that the activation and
degranulation of mast cells that are induced by antigens and
the migration of mast cells toward antigens are important
pathogenic mechanisms in allergic diseases. In the present
study, we demonstrated that the number of mucosal mast
cells was greatly increased in the proximal colons of FA
mice, and the increase was reduced following the treatment
with ZF or DMS. However, the mechanism by which these
mucosal mast cells migrate to sites of allergy reaction in the
colon is not fully understood. It has been reported that DMS
can inhibit the movement of RBL-2H3 cells toward antigens
[19]. Furthermore, the downregulation of Sphk1 expression
using small interfering RNA completely blocks the migration
toward antigens in RBL-2H3 cells [19]a n dh u m a nm a s tc e l l s
[20], whereas the downregulation of Sphk2 has no eﬀect
[19, 20]. Thus, these ﬁndings suggest that ZF downregulates
Sphk1 expression and thereby suppresses both the activation
of mast cells that are induced by the antigens and the
migration of mast cells toward the antigens. Furthermore,
ZanthoxyliFructusisoneoftheherbalconstituentsinFAHF-
1andFAHF-2whichshowinhibitionofsystemicanaphylaxis
and suppression of histamine release in a murine model of
food allergy [13, 14]. In particular, FAHF-2 has inhibitory
eﬀectsonperipheralbloodbasophilsfrompatientswithfoodEvidence-Based Complementary and Alternative Medicine 11
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Figure 6: The eﬀect of ZF and DMS on the development of FA in vivo. (a) The induction of allergic diarrhea was compared between the
vehicle-andZF-treatedgroups.ZFwasorallyadministeredduringtheinductionofallergicdiarrheabyOVAoralchallengeasdescribedinthe
M a t e r i a l sa n dM e t h o d ss e c t i o n( n = 8). (b) DMS (1mg/kg) suppressed the incidence of allergic diarrhea (n = 5–8). (c) The proximal colons
of the vehicle, ZF (320mg/kg), and DMS (1mg/kg) treated mice after oral challenge with OVA were stained with anti-mMCP1 antibody.
The scale bar represents 200μm. (d) The expression levels of IL-4 and sphk1 in the proximal colons were measured using real-time PCR.
The results are expressed as the relative ratio to the proximal colons of the vehicle-treated FA mice. The data are expressed as the mean ± SD
(n = 5). ∗P<0.05 compared with the vehicle.
allergy [15]. These previous studies may further support the
ﬁndings of this study that ZF may have a potential for food
allergy treatment. Taken all together, it is suggested that ZF
may provide a novel strategy for the treatment of FA via
inhibition of the Sphk pathway.
Although the active compounds in ZF have not yet been
identiﬁed, ZF provides novel insights into the development
of a therapeutic drug against both Sphk1-dependent and -
independent mechanisms of FA that are closely related to the
activity of mucosal mast cells. Furthermore, ZF or its active
constituents may provide a novel prototype for antiallergic
agents that act via the inhibition of Sphk1-dependent and -
independent pathways.
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